

SANOFI AT ATTD 2020

February 19–22
Madrid, Spain

SANOFI'S COMMITMENT AND CONTRIBUTION TO ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES (ATTD) 2020

We are proud to reinforce our commitment for advancing innovation in diabetes at this year's **ATTD**, with more than **10 scientific contributions to the program**.

Sanofi's engagement at ATTD illustrates our comprehensive approach to creating a connected ecosystem that aims to help improve day-to-day diabetes management and furthers individualization of care. Our vision is to enable every individual using insulins to better manage their diabetes, underpinned by technology, medicines and education initiatives that improve health outcomes.

We are delighted to announce that we will be holding a symposium outlining this approach in more detail. In addition, we are presenting new evidence from across our diabetes portfolio. Highlights include:

SANOFI SYMPOSIUM

Precise goals, personalized paths:

The digital approach for diabetes management

Friday, February 21.
15:00–16:30,
Auditorium A.

The symposium will explore how insulin tools and treatments can evolve to help address unmet needs in people with diabetes. Speakers will also discuss how integrated care solutions can incorporate these tools within an ecosystem that encourages patients, their families and physicians to engage with their individual care and the role of data and analytics.

My Dose Coach™ study:

Exploring the real-world effectiveness of digital technology on blood sugar control

This new study assesses the effect of the titration optimization app, My Dose Coach™, on management of type 2 diabetes in people using basal insulin. We are presenting two posters, the first of which measures attainment of blood sugar targets and hypoglycemia. Poster two examines quality of life measures in the same population, including changes in self-reported well-being on the World Health Organization's Five Well-Being Index.

Romero-ibarguengoitia, M.E, et al. Posters 100 & 430, 20.2.2020, E-Poster Area.

The BRIGHT trial:

Sub-analyses build on results from BRIGHT head-to-head clinical trial

The post-hoc sub-analyses evaluate blood sugar control in adults with type 2 diabetes at high risk of hypoglycemia due to age (post-hoc) or impaired renal function (pre-specified), comparing Toujeo® (insulin glargine 300 Units/mL) vs insulin degludec 100 Units/mL.

Cheng A., et al. Poster 378, 20.2.2020, E-Poster Area.

InRange:

Evaluating the impact of time spent in blood sugar range on clinical and quality of life outcomes

InRange is an ongoing head-to-head study that assesses the clinical efficacy of Toujeo® (insulin glargine 300 Units/mL) and insulin degludec 100 U/mL in people with type 1 diabetes. Our presentation provides insight into the study methodology that aims to measure time in range, glucose variability and occurrence and frequency of hypoglycemia.

Edelman, S., et al. Poster 379, 20.2.2020, E-Poster Area.

iGlarLixi meta-analysis:

Comparing treatment intensification options in type 2 diabetes

The new network meta-analysis compares the efficacy of Soliqua®* (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) vs insulin degludec/insulin aspart in controlling blood sugar and incidence of hypoglycemia and weight change.

Jammah, A.A, et al. Poster 394, 20.2.2020, E-Poster Area.